MariaColavincenzoMD

Dermatology • Chicago, IL

Assistant Professor in Dermatology, Northwestern University Medical School

Join to view full profile

Dr. Colavincenzo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Colavincenzo's full profile

Already have an account?

Office
676 N Saint Clair St
Suite 1600
Chicago, IL 60611
Phone+1 312-695-8106

Fax+1 312-695-0537

Education & Training

New York Presbyterian Hospital (Cornell Campus)Residency, Dermatology, 2005 - 2008
McGaw Medical Center of Northwestern UniversityInternship, Internal Medicine, 2004 - 2005
Perelman School of Medicine at the University of PennsylvaniaClass of 2004

Certifications & Licensure

IL State Medical License 2009 - 2026
NY State Medical License 2005 - 2010
American Board of Dermatology Dermatology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011

Clinical Trials

Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash Start of enrollment: 2008 Apr 03
Completed
Phase 1

Publications & Presentations

PubMed

Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study.
Tejashri Venkatesh, Victor L Quan, Edward B Li, Maria L Colavincenzo
Journal of the American Academy of Dermatology. 2024-09-24
16 citations
A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata.
Daniela Mikhaylov, Jacob W Glickman, Ester Del Duca, John Nia, Peter Hashim
Archives of Dermatological Research. 2023-03-01
38 citations
Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata.
Brett King, Natasha Mesinkovska, Paradi Mirmirani, Suzanne Bruce, Steve Kempers
Journal of the American Academy of Dermatology. 2022-08-01

Press Mentions

Twelve Signs of Hair Loss to Bring up to Your DermatologistAugust 21st, 2020
As More Young Men Use a Hair Loss Drug, Some Doctors Caution About Rare Side EffectsJune 12th, 2024